Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model

2010 ◽  
Vol 400 (2) ◽  
pp. 207-212 ◽  
Author(s):  
Yanni Xu ◽  
Juan Wang ◽  
Yi Bao ◽  
Wei Jiang ◽  
Lian Zuo ◽  
...  
2020 ◽  
Vol 43 (11) ◽  
pp. 1479-1482 ◽  
Author(s):  
Mingzhu Liu ◽  
Hehe Xiao ◽  
Siting Wu ◽  
Qing Yu ◽  
Pengfei Li

2021 ◽  
Vol 22 (17) ◽  
pp. 9505
Author(s):  
Rui Zhang ◽  
Caili Qiao ◽  
Qiuyan Liu ◽  
Jingwen He ◽  
Yifan Lai ◽  
...  

Depression is the most frequent affective disorder and is the leading cause of disability worldwide. In order to screen antidepressants and explore molecular mechanisms, a variety of animal models were used in experiments, but there is no reliable high-throughput screening method. Zebrafish is a common model organism for mental illness such as depression. In our research, we established chronic unpredictable mild stress (CUMS) models in C57BL/6 mice and zebrafish; the similarities in behavior and pathology suggest that zebrafish can replace rodents as high-throughput screening organisms. Stress mice (ip., 1 mg/kg/d, 3 days) and zebrafish (10 mg/L, 20 min) were treated with reserpine. As a result, reserpine caused depression-like behavior in mice, which was consistent with the results of the CUMS mice model. Additionally, reserpine reduced the locomotor ability and exploratory behavior of zebrafish, which was consistent with the results of the CUMS zebrafish model. Further analysis of the metabolic differences showed that the reserpine-induced zebrafish depression model was similar to the reserpine mice model and the CUMS mice model in the tyrosine metabolism pathway. The above results showed that the reserpine-induced depression zebrafish model was similar to the CUMS model from phenotype to internal metabolic changes and can replace the CUMS model for antidepressants screening. Moreover, the results from this model were obtained in a short time, which can shorten the cycle of drug screening and achieve high-throughput screening. Therefore, we believe it is a reliable high-throughput screening model.


Molecules ◽  
2014 ◽  
Vol 19 (8) ◽  
pp. 12699-12709 ◽  
Author(s):  
Fang Xu ◽  
Hong Chen ◽  
Xuelan He ◽  
Jingyi Xu ◽  
Bingbing Xu ◽  
...  

2010 ◽  
Vol 15 (3) ◽  
pp. 239-250 ◽  
Author(s):  
Li Wang ◽  
Yi Bao ◽  
Yuan Yang ◽  
Yexiang Wu ◽  
Xiaofang Chen ◽  
...  

CD36, a member of the class B scavenger receptor, is a high-affinity receptor for oxidatively modified low-density lipoprotein (oxLDL). Extensive evidence points to a significant role of CD36 in atherosclerosis and suggests that CD36 could be a potential target for treatment of atherosclerosis. Here, the extracellular domain of human CD36 (Gly30-Asn439) was expressed in Escherichia coli as His6-tagged soluble CD36 (sCD36), which could bind oxLDL specifically and effectively inhibit the uptake of oxLDL by murine macrophage RAW 264.7 cells. An enzyme-linked immunosorbent assay (ELISA)–like high-throughput screening (HTS) assay was developed for the discovery of CD36 antagonists, based on the competition of sCD36 binding to immobilized oxLDL and detection with a monoclonal antibody against His-tag. This assay was suitable for HTS in a 96-well format and was robust and reliable according to the evaluation parameter Z′ value of 0.82. The developed HTS assay was applied to both pure chemical compounds and microbial secondary metabolite crude extracts to identify CD36 antagonists. Three active compounds—sodium danshensu (DSS), rosmarinic acid (RA), and salvianolic acid B (SAB)—were shown to be antagonistic to sCD36-oxLDL binding and further validated by their inhibition of oxLDL uptake in RAW 264.7 cells. These results suggest that the ELISA-like assay represents a promising screening for identifying bioactive molecules targeting atherosclerosis at the level of CD36-ligand binding.


Author(s):  
Marcela M. Fernandez-Gutierrez ◽  
◽  
Peter P. J. Roosjen ◽  
David B. H. van Zessen ◽  
Jerry M. Wells ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document